GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avax Technologies Inc (OTCPK:AVXT) » Definitions » Cash And Cash Equivalents

Avax Technologies (Avax Technologies) Cash And Cash Equivalents : $0.35 Mil (As of Sep. 2008)


View and export this data going back to . Start your Free Trial

What is Avax Technologies Cash And Cash Equivalents?

Avax Technologies's quarterly cash and cash equivalents declined from Mar. 2008 ($3.26 Mil) to Jun. 2008 ($1.35 Mil) but then stayed the same from Jun. 2008 ($1.35 Mil) to Sep. 2008 ($0.35 Mil).

Avax Technologies's annual cash and cash equivalents declined from Dec. 2005 ($5.57 Mil) to Dec. 2006 ($1.49 Mil) but then increased from Dec. 2006 ($1.49 Mil) to Dec. 2007 ($5.90 Mil).


Avax Technologies Cash And Cash Equivalents Historical Data

The historical data trend for Avax Technologies's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avax Technologies Cash And Cash Equivalents Chart

Avax Technologies Annual Data
Trend Dec98 Dec99 Dec00 Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.13 1.56 5.57 1.49 5.90

Avax Technologies Quarterly Data
Dec03 Mar04 Jun04 Sep04 Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.68 5.90 3.26 1.35 0.35

Avax Technologies Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Avax Technologies  (OTCPK:AVXT) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Avax Technologies Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Avax Technologies's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Avax Technologies (Avax Technologies) Business Description

Traded in Other Exchanges
N/A
Address
9200 Indian Creek Parkway, Suite 200, Overland Park, KS, USA, 66210
Avax Technologies Inc is a development stage biotechnology company. The company is engaged in the development and commercialization of individualized vaccine therapies and other technologies for the treatment of cancer. It also involved in the development and commercial readiness in the immuno-oncology arena.
Executives
Carl Spana director PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Prendergast John K A director ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017

Avax Technologies (Avax Technologies) Headlines

No Headlines